Investor Presentaiton

Research framework applied to Oncology builds on our scientific depth in immuno-oncology Strategy: Build a portfolio of foundational assets to address key tumor intrinsic and tumor extrinsic mechanisms, where combinations will be critical for durable responses with transformational potential. || || We have deep expertise in tumor extrinsic biology Immune Checkpoints Only company with three approved T cell checkpoint inhibitors (CPIs) Adaptive and Innate Immunity Insights from translational datasets to guide the next-generation of transformational medicines Bristol Myers Squibb™ Stroma Neoantigens Tumor Extrinsic Not for Product Promotional Use 21

View entire presentation